# A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07055594/  
OnCo record `nct07055594` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SOA101 in advanced solid tumours, run by Shine-On Biomedical Co., Ltd., now recruiting.

## Summary

A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07055594 by Shine-On Biomedical Co., Ltd., with 76 participants planned, started 2025-07-30 and due to reach its primary completion in 2028-02. Interventions recorded: SOA101.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07055594
- Phase: 1/2
- Setting: A Phase I/IIa Dose-escalation, Dose-optimization and Dose Expansion Study to Evaluate the Safety and Preliminary Efficacy of Tri-specific Antibody (SOA101) in Subjects With Advanced Solid Tumors.
- Sponsor: Shine-On Biomedical Co., Ltd.
- Enrolled: 76

## Sources

- ClinicalTrials.gov NCT07055594: https://clinicaltrials.gov/study/NCT07055594

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07055594.json